Identification of a 1.2 Kb cDNA fragment from a region on 9p21 commonly deleted in multiple tumor types.
暂无分享,去创建一个
O. Olopade | J. Rowley | J D Rowley | O I Olopade | S Gursky | S. Gursky
[1] D. Quelle,et al. Cancer-associated mutations at the INK4a locus cancel cell cycle arrest by p16INK4a but not by the alternative reading frame protein p19ARF. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[2] R. Takahashi,et al. Contribution of Chromosome 9p21‐22 Deletion to the Progression of Human Renal Cell Carcinoma , 1995, Japanese journal of cancer research : Gann.
[3] J. Rowley,et al. Homozygous deletion of the alpha- and beta 1-interferon genes in human leukemia and derived cell lines. , 1988, Proceedings of the National Academy of Sciences of the United States of America.
[4] O. Olopade,et al. Mapping of the shortest region of overlap of deletions of the short arm of chromosome 9 associated with human neoplasia. , 1992, Genomics.
[5] A. Feinberg,et al. A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity. , 1983, Analytical biochemistry.
[6] S. Scherer,et al. Delineation of multiple deleted regions in 7q in myeloid disorders , 1999, Genes, chromosomes & cancer.
[7] T. Savarese,et al. Codeletion of the genes for p16INK4, methylthioadenosine phosphorylase, interferon-alpha1, interferon-beta1, and other 9p21 markers in human malignant cell lines. , 1996, Cancer genetics and cytogenetics.
[8] W. Foulkes,et al. Loh and mutation analysis of CDKN2 in primary human ovarian cancers , 1995, International journal of cancer.
[9] J. Sambrook,et al. Molecular Cloning: A Laboratory Manual , 2001 .
[10] G. Peters,et al. The p16INK4a/CDKN2A tumor suppressor and its relatives. , 1998, Biochimica et biophysica acta.
[11] A. Brenner,et al. Chromosome 9p allelic loss and p16/CDKN2 in breast cancer and evidence of p16 inactivation in immortal breast epithelial cells. , 1995, Cancer research.
[12] R. Chaganti,et al. Homozygous Deletions and Loss of Expression of the CDKN2 gene occur frequently in head and neck squamous cell carcinoma cell lines but infrequently in primary tumors , 1995, Genes, chromosomes & cancer.
[13] W. Franklin,et al. Identification of a novel region of homozygous deletion on chromosome 9p in squamous cell carcinoma of the lung: the location of a putative tumor suppressor gene. , 1997, Cancer research.
[14] O. Olopade,et al. Molecular analysis of deletions of the short arm of chromosome 9 in human gliomas. , 1992, Cancer research.
[15] J. Stephenson,et al. A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia , 1982, Nature.
[16] M. Boavida,et al. Loss of heterozygosity at chromosome 9p21 in primary neuroblastomas: evidence for two deleted regions. , 1997, Cancer genetics and cytogenetics.
[17] Kathleen R. Cho,et al. Frequency of homozygous deletion at p16/CDKN2 in primary human tumours , 1995, Nature Genetics.
[18] Carissa A. Sanchez,et al. Allelic loss of 9p21 and mutation of the CDKN2/p16 gene develop as early lesions during neoplastic progression in Barrett's esophagus. , 1996, Oncogene.
[19] O. Olopade,et al. Homozygous deletions within chromosomal bands 9p21-22 in bladder cancer. , 1994, Cancer research.
[20] H. Koeffler,et al. Alterations of the p15, p16,and p18 genes in osteosarcoma. , 1996, Cancer genetics and cytogenetics.
[21] Ashutosh Kumar Singh,et al. Rarity of somatic and germline mutations of the cyclin-dependent kinase 4 inhibitor gene, CDK4I, in melanoma. , 1994, Cancer research.
[22] J. Rowley,et al. A method for the rapid sequence-independent amplification of microdissected chromosomal material. , 1992, Genomics.
[23] W. Farrell,et al. Chromosome 9p deletions in invasive and noninvasive nonfunctional pituitary adenomas: the deleted region involves markers outside of the MTS1 and MTS2 genes. , 1997, Cancer research.
[24] M. Skolnick,et al. A cell cycle regulator potentially involved in genesis of many tumor types. , 1994, Science.
[25] X. Estivill,et al. Retention of the CDKN2A locus and low frequency of point mutations in primary and metastasic cutaneous malignant melanoma , 1998, International journal of cancer.
[26] C. Thompson,et al. bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death , 1993, Cell.
[27] D. Dexter,et al. 5'-deoxy-5'-methylthioadenosine phosphorylase--II. Role of the enzyme in the metabolism and antineoplastic action of adenine-substituted analogs of 5'-deoxy-5'-methylthioadenosine. , 1983, Biochemical pharmacology.
[28] C. Sherr,et al. Tumor surveillance via the ARF-p53 pathway. , 1998, Genes & development.
[29] O. Olopade,et al. p16 alterations and deletion mapping of 9p21-p22 in malignant mesothelioma. , 1994, Cancer research.